Avatar
Bristol Myers Squibb Verified account Aggregated content @bmsnews · 2h

#MEDIA: Announcing positive topline results from a Phase 3 trial evaluating our investigational CELMoD agent for adult patients with relapsed or refractory #MultipleMyeloma. https://t.co/6g55GwOGDk https://t.co/eP0UrHuSFW -